Cargando…

Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes

OBJECTIVES: The prognostic significance of the progesterone receptor (PR) has been widely investigated in luminal A and luminal B [human epidermal growth factor receptor 2 (HER2)–] breast cancer subtypes, both of which are estrogen receptor (ER)-positive and HER2-negative. In contrast, few studies h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Utsumi, Toshiaki, Kobayashi, Naomi, Hikichi, Masahiro, Ushimado, Kaori, Kuroda, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fujita Medical Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761818/ https://www.ncbi.nlm.nih.gov/pubmed/35111557 http://dx.doi.org/10.20407/fmj.2020-023

Ejemplares similares

Inverse correlation between Ki67 expression as a continuous variable and outcomes in luminal HER2-negative breast cancer
por: Ushimado, Kaori, et al.
Publicado: (2019)

Differences in clinicopathologic features and subtype distribution of invasive breast cancer between women older and younger than 40 years
por: Ushimado, Kaori, et al.
Publicado: (2019)

Differences in clinicopathologic features and subtype distribution of invasive breast cancer between elderly and non-elderly women
por: Utsumi, Toshiaki, et al.
Publicado: (2021)

A Hypoglycemia-inducing Giant Borderline Phyllodes Tumor Secreting High-molecular-weight Insulin-Like Growth Factor II: Immunohistochemistry and a Western Blot Analysis
por: Hikichi, Masahiro, et al.
Publicado: (2017)

PROGNOSTIC IMPACT OF LOW ESTROGEN AND PROGESTERONE POSITIVITY IN LUMINAL B (HER2 NEGATIVE) BREAST CANCER
por: Rajc, Jasmina, et al.
Publicado: (2018)

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer
por: Park, Chansub, et al.
Publicado: (2016)

Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
por: Diana, Anna, et al.
Publicado: (2022)

Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information
por: Inic, Zorka, et al.
Publicado: (2014)

Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype
por: Yanagawa, Masumi, et al.
Publicado: (2012)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score
por: Yang, Zheng‐Jun, et al.
Publicado: (2022)

Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study
por: Zong, Yu, et al.
Publicado: (2014)

Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors
por: Lopez, Gianluca, et al.
Publicado: (2019)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China
por: Li, An-qi, et al.
Publicado: (2015)

Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
por: Fan, Ying, et al.
Publicado: (2015)

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2015)

Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
por: Hefti, Marco M, et al.
Publicado: (2013)

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer
por: Yoder, Rachel, et al.
Publicado: (2022)

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
por: Liu, Xi-Yu, et al.
Publicado: (2018)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

TIMAP Upregulation Correlates Negatively with Survival in HER2- Negative Subtypes of Breast Cancer
por: Obeidat, Marya, et al.
Publicado: (2021)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
por: Alvarez-Lopez, I., et al.
Publicado: (2020)

A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
por: Yang, Xue, et al.
Publicado: (2023)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer
por: Yue, Yuhan, et al.
Publicado: (2022)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Unusual Gastric Metastasis in Triple-Negative (Estrogen Receptor/Progesterone Receptor/HER2neu Negative) GATA-Binding Protein 3-Positive Breast Cancer
por: Baa, Annie Kanchan, et al.
Publicado: (2020)

Recurrent Metaplastic Breast Cancer with Subtype Converted from Triple-Negative to HER2-Positive: A Case Report and Literature Review
por: Wu, Jing, et al.
Publicado: (2023)

Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects
por: Albert, Veruschka, et al.
Publicado: (2022)

Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study
por: Eom, Yong Hwa, et al.
Publicado: (2023)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
por: Yang, Fan, et al.
Publicado: (2022)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
por: MacNeil, Ian A., et al.
Publicado: (2020)

SF3B1 mutation is a poor prognostic indicator in luminal B and progesterone receptor-negative breast cancer patients
por: Fu, Xing, et al.
Publicado: (2017)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
por: Laidi, Fatna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a9b8miqufgrqhvcbtitjq4bc4q